European Commission approves Durveqtix (fidanacogene elaparvovec), a one-time gene therapy for adults with hemophilia B – Pfizer
Pfizer Inc. announced that the European Commission (EC) has granted conditional marketing authorization for Durveqtix (fidanacogene elaparvovec), a gene therapy for the treatment of severe and moderately severe… read more.